Lumos Secures FDA CLIA Waiver, Unlocking Broader US Commercial Opportunity for FebriDx

About Lumos Diagnostics Holdings Limited

Lumos Diagnostics Holdings Limited (ASX: LDX) is a point-of-care diagnostics company focused on improving the diagnosis and management of acute infectious and inflammatory conditions. The company develops and commercialises rapid, clinically actionable tests designed to deliver results in minutes and support more targeted treatment decisions at the point of care. Lumos combines proprietary assay technologies, connected digital reader platforms and scalable manufacturing capabilities to provide solutions for its own products and for healthcare and life sciences partners globally.

FDA CLIA waiver materially expands FebriDx’s market opportunity

A central driver of Lumos’ latest momentum is the FDA’s granting of a CLIA waiver for FebriDx following 510(k) clearance. This is a major commercial milestone because it expands where FebriDx can be used in the United States. Prior to the waiver, FebriDx was limited to moderate-complexity clinical settings, which largely restricted use to hospital and laboratory environments. With the waiver now granted, the product can be used in a much broader range of healthcare settings that hold a Certificate of Waiver, including primary care physician offices, urgent care clinics, retail health and pharmacy clinics, and community health centres.

The scale of the opportunity is significant. Lumos said the CLIA waiver expands applicability to approximately 80 million US patients per annum and to more than 300,000 locations across the country. The company also said this represents a US$1.0+ billion market opportunity, around 15 times larger than the opportunity available under the previous moderate-complexity classification. This matters because it shifts FebriDx from being a product with more limited institutional use to one with much broader outpatient potential, materially increasing its commercial relevance across the US healthcare system.

Milestone payments and commercial partnerships strengthen the near-term outlook

The CLIA waiver also has an immediate financial benefit. Lumos said the approval triggers a US$5.0 million payment from Phase Scientific under its exclusive US distribution agreement for FebriDx, as well as a US$507,377 milestone payment under its BARDA contract for achieving FDA CLIA waiver. These receipts provide additional support for the balance sheet and strengthen funding available for the next stage of US rollout.

Lumos’ existing commercial partnerships are also important in this context. The company said its US commercial strategy is supported by Phase Scientific, PRO-spectus and AcuityMD, with a focus on healthcare provider education, integration into outpatient clinic workflows and securing reimbursement from private payors. That suggests the FDA milestone is not an isolated regulatory event, but part of a broader plan to translate product approval into market penetration and adoption. In other words, Lumos now has both a larger market and an emerging pathway to address it.

Fresh capital supports broader US launch and execution

Alongside the FDA announcement, Lumos completed a A$20.0 million institutional placement to fund broader commercialisation of FebriDx in the US. The company said institutional demand substantially exceeded the A$20.0 million sought to be raised, indicating strong investor support at what management described as an important inflection point. The placement was priced at A$0.225 per share, with one free-attaching unlisted option for every two placement shares, exercisable at A$0.34 and expiring on 31 December 2027.

Lumos also announced a Share Purchase Plan targeting about A$2.0 million, giving eligible shareholders in Australia and New Zealand the opportunity to participate on the same pricing terms as the placement. In addition, the company received written confirmation that existing shareholders Tenmile and Ryder Capital will exercise at least a combined 43.9 million options, providing a further A$3.1 million of funding. Combined with the placement and SPP proceeds, Lumos said it is confident it can execute the growth plans outlined for FebriDx in the US.

The use of proceeds is directly aligned to execution. Lumos said funds will be applied towards increasing manufacturing capacity for FebriDx by expanding operations at its Carlsbad, California facility, building sales and marketing capability, supporting a medical implementation team for the US launch, initiating feasibility work for additional proprietary products, repaying amounts drawn under the company’s loan facility, and supporting general working capital. This is important because the key challenge after regulatory approval is scaling operations and commercial capability quickly enough to capture the opportunity. Lumos’ latest capital raising is aimed squarely at that next phase.

Product positioning supports clinical relevance in acute respiratory care

The commercial case for FebriDx is underpinned by its clinical use case. Lumos described FebriDx as a rapid point-of-care test that helps healthcare professionals differentiate between bacterial and non-bacterial respiratory infections after 10 minutes. This supports more informed clinical decision-making and may help reduce unnecessary antibiotic prescribing. In a primary care and urgent care environment, speed and simplicity are especially important, which makes the CLIA waiver strategically meaningful. It allows FebriDx to be used more widely without complex laboratory infrastructure or specialised training, improving access at the time of consultation.

Lumos also highlighted future optionality through a planned paediatric initiative. Management said that, with ongoing support from BARDA, the company sees an opportunity to broaden access further through its paediatric study. If successful, this could extend the use of FebriDx to children aged 2 to 12 years, broadening the age range of patients who may benefit from the test. While that remains prospective, it points to further expansion potential beyond the current approval.

Outlook

Looking ahead, Lumos appears to be moving into a more commercially significant phase. The FDA CLIA waiver for FebriDx materially broadens the company’s US addressable market, unlocks milestone payments and enables access to outpatient settings across more than 300,000 locations. At the same time, the A$20.0 million placement, proposed A$2.0 million SPP and additional option exercise funding provide capital to expand manufacturing capacity and support US sales, marketing and implementation. While commercial execution remains critical, Lumos now has regulatory clearance, expanded market access, partnership support and fresh funding aligned behind the broader US rollout of FebriDx.